Navigation Links
Verified Clinical Trials System Implemented at Leading Global Contract Research Organization to Improve Participant Safety and Data Integity
Date:2/2/2012

GARDEN CITY, N.Y., Feb. 2, 2012 /PRNewswire-iReach/ -- Verified Clinical Trials, LLC and Celerion today announced their partnership in the fight against multiple simultaneous clinical trial enrollment in the medical research industry. With the poor economy and intensified recruitment techniques, the medical research industry has seen a tremendous increase in 'professional' research participants enrolling in multiple clinical trials simultaneously. This problem has infiltrated into not only healthy participant clinical trials, but all phases of research involving all disease entities.

(Logo: http://photos.prnewswire.com/prnh/20120202/CG46822)

Dr. Mitchell Efros, President and CEO of Verified Clinical Trials , along with his team of research professionals, developed Verified Clinical Trials, a comprehensive and unique research participant database registry to enhance the safety and quality of both early and late stage clinical trials globally. The system is designed for wide scale deployment for every major Contract Research Organization (CRO) and research site globally, to assist in the goal for improved participant safety and data integrity.

"We specifically chose to partner with Celerion, a leader in innovative early stage clinical research solutions, as a key part of our research and development strategy. Celerion has the largest Phase I bed capacity globally and sets the standard to protect their research participants and enhance data integrity," stated Dr. Efros.

"This is a very exciting time for Verified Clinical Trials as we further develop our innovative processes and strengthen our network with the goal of improving clinical participant safety and research data quality," said Dr. Efros. "Celerion intends to have clinical participants 'verified' through the Verified Clinical Trials system to ensure that only qualified participants proceed into screening, thereby saving the Sponsor and sites time and money."

Verified Clinical Trials plans to have nearly all of the most recognized CROs utilizing their system in 2012. Additionally, Verified Clinical Trials continues to enlist a significant cohort of the world's largest pharmaceutical companies. In addition to verifying a research participant is not involved in any other phase of clinical research simultaneously, Verified Clinical Trials offers many other unique value added services for both early and late phase sites to reduce overall cost of the trial and reduce liabilities.

"It is great news for the entire clinical research community that Verified Clinical Trials is boosting its presence and will have major affiliates in so many locations," said Phil Bach, Vice President of Global Clinical Research at Celerion. "The implementation of the Verified Clinical Trials solution at Celerion supports our commitment to apply rigorous standards to protect the safety of participants and enhance data integrity for Sponsors. This implementation sets a standard in the industry to continue to improve clinical research and bring new drugs to the market place."

Verified Clinical Trials has also secured its presence in later phase trials with major pharmaceutical companies.

About Verified Clinical Trials (VCT)

Verified Clinical Trials (VCT) was developed by experts active in the clinical research community to proactively improve clinical research participant safety and data quality in clinical research trials. Verified Clinical Trials defines itself as the world's leader in the field of database registries in clinical trial research, and is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value added services to the clinical research site, CRO, and Pharmaceutical Sponsor, that prove invaluable with regards to financial and legal issues and liabilities. For more information, visit www.verifiedclinicaltrials.com.

About Celerion

Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com

Media Contact:
Kerri Weingard, ANP
Chief Operating Officer
Verified Clinical Trials
+1 516 998-7499
KWeingard@verifiedclinicaltrials.com

Farzana Azam
Senior Director, Global Marketing
Celerion
+1 (647) 261 3628
media.inquiries@celerion.com

Media Contact: kerri weingard verified clinical trials, 5169987499, kweingard@verifiedclinicaltrials.com  

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Verified Clinical Trials
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready
2. Origins of wolverine in California genetically verified
3. A new journal where molecular biology meets clinical research
4. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
5. Biochemistry of human physiology in health and disease is focus of updated clinical text
6. New book helps medical students master clinical skills
7. In just 5 years, gene discovery to clinical trial of potential treatment
8. Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29
9. Genome Medicine: Bridging the gap between research and clinical practice
10. 3 new informatics pilot projects to aid clinical and translational scientists nationwide
11. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
(Date:2/4/2016)... ... February 04, 2016 , ... Franz Inc. , an ... technology has been recognized As “ Best in Semantic Web Technology - USA ... Corporate America, it’s our priority to showcase prominent professionals who are excelling in ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... of potential targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved ... monoclonal antibody therapeutics for Alzheimer’s. , Following on from the first misfolded Amyloid ...
Breaking Biology Technology: